Compare CMRE & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | SRPT |
|---|---|---|
| Founded | 1974 | 1980 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2010 | 2000 |
| Metric | CMRE | SRPT |
|---|---|---|
| Price | $14.03 | $17.93 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 29 |
| Target Price | $12.00 | ★ $25.85 |
| AVG Volume (30 Days) | 337.2K | ★ 3.0M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.99 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $5.55 | $5.74 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $10.84 | $14.68 |
| 52 Week High | $18.06 | $25.32 |
| Indicator | CMRE | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 32.92 | 59.29 |
| Support Level | N/A | $15.29 |
| Resistance Level | $17.76 | $18.16 |
| Average True Range (ATR) | 0.49 | 0.80 |
| MACD | -0.13 | 0.24 |
| Stochastic Oscillator | 0.96 | 97.68 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.